22/03/2026
New evidence on sedation during therapeutic hypothermia in neonatal HIE.
Dexmedetomidine during therapeutic hypothermia ↓ opioid use by 50% while maintaining effective sedation. The study also identified an optimal dosing range (0.25–0.5 μg/kg/hr) that balances strong sedation with a favorable safety profile, helping guide more precise and evidence-informed care. Findings support dexmedetomidine as a viable first-line sedative during therapeutic hypothermia and inform safer dosing strategies.
Full Article: https://pubmed.ncbi.nlm.nih.gov/41748747/